Søgning


Flere søgeindstillinger

Søgning på udtrykket 'hiv' giver 80 resultater


Dokumenter [21] Sider [7] Kalender [3] Nyt fra tidsskrifterne [+20] Aktuelle smitsomme sygdomme [+20]
Dokumenter [21]

Europæisk guideline om hvornår, der bør testes for HIV. Udgivet af "HIV in Europe", et paneuropæisk initiativ for tidligere diagnosticering og behandling af HIV. Kort version på dansk kan findes på www.eurotest.org/projects-collaborations/indicator-condition-guided-hiv-testinghides/guidance-hiv-indicator-conditions

Udarbejdet af arbejdsgruppe fra Dansk Selskab for Infektionsmedicin og Dansk Fertilitetsselskab.

Fællesregional retningslinje for udlevering af forebyggende medicin mod HIV (PrEP), udgivet af Danske Regioner.

Udarbejdet af arbejdsgruppe under Dansk Selskab for Infektionsmedicin

Udarbejdet af DSI's arbejdsgruppe vedrørende antiretroviral terapi

Om håndtering og opfølgning for at minimere risiko for smitte med bl.a. HIV, HBV og HCV.

…medicin i form af f.eks TNF-α hæmmere eller andre immunsupprimerende biologiske lægemidler, hvor der er øget risiko for tuberkulosereaktivering. Guideline dækker ikke børn, personer med medfødt immundefekt, HIV positive, patienter i dialyse, patienter med dysreguleret diabetes, silicose, erhvervede immundefekter eller patienter i konventionel kortvarig kemoterapi. Denne guideline omhandler ikke klassisk smitteopsporing blandt tuberkuloseeksponerede eller udredning på mistanke om aktiv tuberkulose.

…r (BMSL) til patienter i forhold til risiko for tuberkulose (TB), Humant Papillom Virus (HPV), Hepatitis B og C (HBV og HCV), Varicella Zoster Virus (VZV), Herpes Simplex Virus (HSV), Cytomegalovirus (CMV), Epstein Barr Virus (EBV) og Humant Immundefekt Virus (HIV) og øvrige infektioner. Vejledningen er udarbejdet af repræsentanter fra Dansk Selskab for Gastroenterologi og Hepatologi (DSGH), Dansk Reumatologisk Selskab (DRS), Dansk Dermatologisk Selskab (DDS) og Dansk Selskab for Infektionsmedicin (DSI).

Arrangeret af Yngre Infektionsmedicinere

Bl.a. om HIV, hepatitis, resistente bakterier og immundefekt

Bl.a. om HIV, hepatitis, influenza og CNS infektioner

Bl.a. om HIV, hepatitis, cystisk fibrose og nye guidelines

Correspondence regarding "Use of statins and risk of AIDS-defining and non-AIDS-defining malignancies among HIV-1 infected patients on antiretroviral therapy"

DANHIV blev oprettet som en regional klinisk kvalitetsdatabase i RegionH i sommeren 2015. Imidlertid har projektet fungeret som Det Danske HIV Kohorte Studie (DHK) siden 1998. DHK har fungeret som en kombineret kvalitetsdatabase og forskningsdatabase. Data i DHK går tilbage til 1. januar 1995, hvorfor vi allerede nu kan vise udviklingen over en lang årrække for de forskellige indikatorer.

Bl.a. om sygdom efter udlandsrejse, resistens og kroniske virale infektioner

Forfattet af DSI's arbejdsgruppe vedrørende antiviral behandling

Bilag til Retningslinjer for screening og profylakse før behandling med biologiske lægemidler (2023)

Sider [7]

…nter 1). Kort over Hvidovre Hospital: www.hvidovrehospital.dk/praktisk-information/transport/Documents/Kort%20over%20Hvidovre%20Hospital.pdf. Delkursusledere: Ole Søgård og Lene Ryom. Formål: At kursisten skal opnå en forståelse af HIV-infektionen, herunder viden om dens epidemiologi, patogenese, diagnose, forebyggelse, behandlingsmulighederne og prognose.

Formål: At kursisten skal opnå en forståelse af HIV-infektionen herunder viden om dens epidemiologi, patogenese, patofysiologi, diagnose, forebyggelse, behandlingsmuligheder og prognose samt viden om diagnostik og behandlingen af AIDS-definerende sygdomme og de hyppigste sexuelt overførte sygdomme. Tid og sted: Hvidovre Hospital. Lokale 10 i undervisningsbygningen. Delkursusledere: Ann-Brit Eg Hansen og Ole Kirk. Program: Mandag 3.

…me og biologisk terrorisme. Specialet er karakteriseret ved et sygdomspanorama hvor sygdommenes prævalens såvel som incidens ændres hurtigt på lokalt og globalt plan. Over de seneste tyve år har specialet udviklet sig til at håndtere behandlingen af HIV og AIDS. I de seneste år er nye alvorlige infektionssygdomme som SARS, fugleinfluenza, West Nile virus, Hanta virus, Nipah virus, og Hendra virus tilkommet.

…na Weis, Britta Tarp, Lone Mygind National Strategi for Hepatitis C (Sundhedsstyrelsen 2023), Kronisk viral hepatitis: Nina Weis (tovholder), Peer Brehm Christensen, Alex Lund Laursen Hepatitis B (2018), Hepatitis C (2022), HIV: Antiretroviral terapi: Jan Gerstoft (tovholder), Jens Lundgren, Henrik Nielsen, Alex Laursen, Niels Obel, Isik Somuncu, Gitte Kronborg, Ann-Brit Eg Hansen Antiviral behandling af hiv smittede personer (2024), Fertilitetsbehandling ved HIV og.

…giske infektioner og kronisk hepatitis: Dato for næste kursus 2026: Sted. Odense Universitetshospital Delkursusledelse. Lone Mygind, Micha Jepsen og Belinda Mössner Tidligere kurser. 4. og 5. december 2023 3. og 4. december 2020 HIV-infektion: Næste kursus. 30. og 31. oktober 2025 (2 dage): Sted. Aarhus Universitetshospital (AUH)  Delkursusledelse. Ole Schmeltz Søgaard og Lene Ryom Nielsen  Program. Afventer Tidligere kurser. 12. og 13. oktober 2022 7.

…me og biologisk terrorisme. Specialet er karakteriseret ved et sygdomspanorama hvor sygdommenes prævalens såvel som incidens ændres hurtigt på lokalt og globalt plan. Over de seneste tyve år har specialet udviklet sig til at håndtere behandlingen af HIV og AIDS. I de seneste år er nye alvorlige infektionssygdomme som SARS, fugleinfluenza, West Nile virus, Hanta virus, Nipah virus, og Hendra virus tilkommet.

…iklen summerer på en rimelig afbalanceret måde den globale kontrovers, som 2013 var præget af, om hvorvidt ART skal benyttes som forebyggende middel, som led i en individuel-baseret eller en folkesundsbaseret strategi for at reducere smittespredning af HIV.

Professor Henrik Nielsen kommenterer: Trods indiskutable fremskridt i den farmakologiske behandling af HIV/AIDS er der fortsat områder med plads til forbedring. Blandt patienter i kronisk behandling er HAND (HIV-associated neurocognitive disorder) et af disse eksempler.

Professor Jens Lundgren kommenterer: I 2014 var verden optaget af Ebola udbruddet i Vest Afrika – et udbrud der blev erkendt hurtigt (om end den internationale assistance lod vente på sig). Vedlagte artikel belyser detaljeret hvorledes HIV pandemien startede i 1920’erne og hvor det jo som bekendt tog over 60 år af finde ud at der overhovedet var et problem. Synes artiklen er godt skrevet og giver et indblik i Afrika for 90 års siden og de ingredienser der skulle til for at ud.

Professor Lars Østergaard kommenterer: Jeg vil gerne anbefale vedlagte artikel som julemånedslæsning. Grundene er som følger: 1) Det vises for første gang, at et medikament kan reaktivere latent HIV-virus under samtidig HAART-behandling i en grad, så virus kan påvises i perifert blod. 2) Der er (omend videnskaligt svage) indicier på, at HIV-reservoir kan reduceres hos nogle patienter, og at effekten af det innate immunforsvar er af betydning herfor.

Professor Jens Lundgren kommenterer: I 2015 nåede WHO sit mål om at få 15 million på behandling. START studiet afklarede også at alle HIV+ personer har gavn af at starte på HIV behandling. Der er fortsat mere end 20 millioner der endnu ikke er startet. Hovedparten bor i ressource svage lande hvor adgang til monitorering af HIV mængden er begrænset og behandlingsskift pga behandlingssvigt er derfor primært drevet af klinik og CD4 tals måling.

… dolutegravir, især når det kombineres med TAF fremfor tenofovir DF, forårsager markant vægtøgning. Især hos kvinder med mørk hudfarve. Artiklen gør indtryk af en række grunde:. Da dolutegravir blev markedsført havde det profilen som det eneste HIV præparat uden bivirkninger. Læring: der er ingen medicinske præparater der ikke har nogle bivirkninger, og typen af bivirkninger kan ikke altid forudsiges udfra markedsføringsstudier (fase I-III).

Professor Jens Lundgren kommenterer: Første lægemiddel mod SARS-CoV-2 udviklet fra ”bunden” – bruger et gammel trick fra HIV medicinen (ritonavir) for at holde plasma koncentrationerne oppe. Læringen er, at det tager tid at lave nye lægemidler helt fra bunden, men det er noget nær en verdensrekord så hurtigt som det skete under pandemien – både hvad angår vacciner (hvor det tog < 1 år fra design ex vivo til markedsføring), men altså ca 2 år for lægemidler som dette.

Professor Lars Østergaard kommenterer: Indimellem kommer der studier, som er så overbevisende, at det sætter en ny behandlingsstandard. Det kan f.eks.

Professor Troels Lillebæk kommenterer: Interessant systematisk review i AIDS om udbytte af screening for tuberkulose infektion (TBI) blandt personer, der lever med HIV (PLHIV) i tuberkulose lav-incidens lande (som Danmark) . Inddraget i alt 51 undersøgelser med 65.930 PLHIV hvoraf 12 % havde en positiv LTBI-test, som var stærkt relateret til oprindelsesland og eksponering for TB ).


Kalender [3]
30. oktober, Aarhus Universitetshospital (AUH)
4. juni, Barcelona, Spanien
4. juni, Barcelona, Spanien
Nyt fra tidsskrifterne [+20]

Der er mere end 20 resultater, måske du vil se flere resultater her?

JAMA Network Open New Online
30.04.2025
This consensus statement examines solutions to the ethical, social, and legal challenges with consent processes for adolescents and young adults in HIV studies in low- and middle-income countries.
Clinical Infectious Diseases
30.04.2025
…he necessity for continuous monitoring.Methods . The study was conducted across 31 provincial-level administrative divisions of China. Demographic information and blood samples were collected from participants at diagnosis of human immunodeficiency virus (HIV) infection between April and June 2023. TDR and molecular transmission networks were analyzed based on partial pol sequences via the Stanford HIV drug resistance database and HIV-TRACE, respectively.
Clinical Infectious Diseases
29.04.2025
…rican American race (vs. white race, within HIC, HR: 1.65(1.19,2.27)), family history of premature CVD (HR: 1.53(1.16,2.03)), current cigarette smoking (HR: 2.27(1.65,3.13)), hypertension (HR: 1.77(1.36,2.30)), lower HDL cholesterol (HR: 1.21(1.10,1.34)), HIV-1 RNA ≥lower-limit-of-quantification (LLQ) (HR:1.40(1.0,1.97)), and a select ART regimen class combination (HR:1.53(1.01,2.31)). Individuals from HIC had a higher risk of first MACE vs. those from other regions, excepting South Asia.
Journal of Infectious Diseases
26.04.2025
Abstract . Introduction . Although antiretroviral therapy (ART) can suppress plasma viral loads in people living with HIV-1 (PLWH), it cannot eliminate HIV-1 proviruses persisting in various tissue reservoirs, and HIV-1 will rebound after ART cessation. We have recently identified the appendix as a novel HIV tissue reservoir, but nothing is known about the provirus and the cellular tropism in this tissue.Methods .
BMC Infectious Diseases
26.04.2025
. Objective. This study evaluates the efficacy, safety, and cost-effectiveness of INSTI-based antiretroviral regimens compared to the national standard first-line treatment EFV/3TC/TDF for HIV/AIDS in China. The aim is to guide clinical decision-making and improve HIV/AIDS prevention and treatment. . Methods.
JAMA Network Open New Online
26.04.2025
Substance Use and Addiction
JAMA Network Open New Online
26.04.2025
This cohort study analyzes the prevalence of alcohol use disorder (AUD) diagnoses among commercially insured individuals who take preexposure prophylaxis (PrEP) as well as clinical and demographic characteristics associated with AUD.
Clinical Infectious Diseases
26.04.2025
Abstract . The promising results of the Ambition-CM trial in persons with HIV have sparked interest in treating non-HIV-associated cryptococcal meningitis with single 10mg/kg liposomal amphotericin B, combined with oral flucytosine and fluconazole. However, caution is warranted when applying this approach to non-HIV organ transplant recipients, whose immune status may vary due to the effects of immunosuppressive drugs.
Clinical Infectious Diseases
26.04.2025
Journal of Acquired Immune Deficiency Syndromes
25.04.2025
Objective: . We sought to characterize the frequency of amyloid-PET positivity among older cognitively impaired people with HIV (PWH) compared to cognitively unimpaired people without HIV (PWoH). We also examined the neuropsychological profiles of the PWH group by amyloid-PET status, cross-sectionally and longitudinally. Methods: . Virally suppressed PWH were sought for a study of HAND where amyloid-PET positivity was used to exclude the possibility of AD.
Journal of Infectious Diseases
25.04.2025
…herapy (ART) are rising in low- and middle-income countries, resulting in a potentially increased use of doravirine-containing ART use. There are knowledge gaps regarding doravirine and hormonal contraceptive drug-drug interactions among women living with HIV (WLWH).Methods . We conducted a five parallel group, prospective pharmacokinetic study among WLWH aged 18-45 years in Johannesburg, South Africa between November 2021 and February 2024.
BMC Infectious Diseases
25.04.2025
. Background. Talaromycosis has long been considered to be exclusively associated with human immunodeficiency virus/acquired immune deficiency syndrome (HIV/AIDS). In recent years, with effective control measures for HIV, the number of talaromycosis patients without HIV infection has been increasing annually. All of these patients have various immunosuppressive factors, including tumors.
BMC Infectious Diseases
25.04.2025
… Intestinal parasitic infections constitute one of the stubborn public health issues, particularly in low- and middle-income countries. This study aimed to investigate the prevalence and diversity of intestinal parasites and protozoa among HIV/AIDS patients in a medical center in Zinder, Niger Republic. . Methods. A total of 224 HIV-immunocompromised patients were hospitalized for acute febrile gastroenteritis.
BMC Infectious Diseases
25.04.2025
. Background. Globally, Human immunodeficiency virus (HIV) testing service acceptance increased impressively in every regions. In spite of this fact, in the majority of the Sub-Saharan African countries more than half of the people living with Human immunodeficiency virus are not aware of their sero-status. Particularly, key and priority populations are understudied compared to other population segment.
AIDS
25.04.2025
Objective: . Although understudied, anecdotal evidence suggests spiritual/religious intimate partner abuse may be prevalent among women living with HIV/AIDS in sub-Saharan Africa and Ghana. This paper examines the prevalence and effects of spiritual/religious intimate partner abuse—spiritual coercion and spiritual control—on the psychosocial (depression) and sexual health (unwanted pregnancies) outcomes of women living with HIV/AIDS in Ghana. Methods: .
AIDS
25.04.2025
Objectives: . This study aimed to estimate the prevalence of M. genitalium infection and understand the patterns of resistance associated mutations (resistance hereafter) in people living with HIV (PLWH). Methods: . We searched PubMed-MEDLINE, Embase and Web of Science to identify studies published as of 31st December 2023, reporting the prevalence of M. genitalium infection in PLWH. The pooled prevalence of M. genitalium infection and its resistance was calculated using random-effect models. Results: .
AIDS
25.04.2025
Objective: . Estimate the independent contributions of in-utero HIV exposure and post-natal environment on neurodevelopment at 24 months of age. Methods: . We recruited mother-infant pairs from 2018–2022 during the second trimester of pregnancy in Malawi. Children who were HIV exposed and uninfected (CHEU) and children unexposed to HIV and uninfected (CHUU) were followed to 24 months of age for neurodevelopmental outcomes. Environmental data was collected at 18 or 24 months.
AIDS
25.04.2025
…nstrated the noninferiority of a triple antiretroviral therapy (ART) taken 4 consecutive days on and 3 days off (hereafter referred to as a 4/7-days strategy) compared to a triple therapy taken 7 days a week (7/7-days strategy) for persons living with HIV and with suppressed viremia. We investigated corresponding cost-effectiveness issues. Design: . Cost-effectiveness study. Setting: . France. Subject, participants: .
AIDS
25.04.2025
…tive: . Epstein-Barr virus (EBV) is linked to both AIDS-defining and non-AIDS defining malignancies. This study investigated the variation and trajectory of blood EBV DNA load after antiretroviral treatment (ART) among a prospective cohort of people with HIV (PWH). Design: . Prospective, observational, noninterventional study. Methods: . Newly diagnosed PWH in Taizhou, China (2012–2014) received ART and were followed until December 2022.
AIDS
25.04.2025
…nnan (LAM) testing has been limited by the diagnostic performance of current assays. We assessed the diagnostic accuracy of the re-engineered TB-LAM SILVAMP (FujjLAM2) assay (Fujifilm, Japan) to diagnose TB amongst hospitalised adults living with advanced HIV disease. Methods: . We consecutively enrolled adults presenting with suspected meningitis at two hospitals in Uganda.
Aktuelle smitsomme sygdomme [+20]

Der er mere end 20 resultater, måske du vil se flere resultater her?

Medscape Infectious Diseases
29.04.2025
Patients in historically redlined neighborhoods experience significantly longer delays in achieving HIV viral suppression than those in non-redlined areas. . Medscape Medical News
Medscape Infectious Diseases
16.04.2025
Despite being effective, PrEP uptake in Europe remains low due to issues like cost, access, and stigma, hindering its potential to reduce HIV transmission. . Medscape Medical News
ProMED
11.04.2025
. . . HIV/AIDS - INDIA (03): (UTTARAKHAND). ************************************. A ProMED-mail post. www.promedmail.org. ProMED-mail is a program of the. International Society for Infectious Diseases. www.isid.org . [1] . Date: Wed 9 Apr 2025 . Source: The Times of India (TOI), Times News Network (TNN) [edited] . timesofindia.indiatimes.com/city/dehradun/23-haridwar-jail-inmates-hiv-positive-dm-seeks-report/articleshow/120136259.cms . . .
Medscape Infectious Diseases
11.04.2025
-The Trump administration plans to remove all the members of a presidential advisory council on HIV/AIDS and provided no timeline for replacing them as the government. . Reuters Health Information
Medscape Infectious Diseases
9.04.2025
Global progress against HIV is at risk as aid cuts could trigger millions of new infections and deaths, potentially setting efforts back to 2010 levels, experts warn. . Medscape Medical News
Medscape Infectious Diseases
9.04.2025
Patients who lose medication access will experience disease progression and risk for death, experts emphasize. . Medscape Medical News
ProMED
1.04.2025
. . . HIV/AIDS - INDIA (02): (TRIPURA, KERALA). ****************************************. A ProMED-mail post. www.promedmail.org. ProMED-mail is a program of the. International Society for Infectious Diseases. www.isid.org . In this post: . [1] Tripura . [2] Kerala . . ****** . [1] Tripura . Date: Wed 26 Mar 2025 . Source: The Indian Express [edited] . indianexpress.com/article/india/tripura-hiv-adults-assembly-cm-manik-saha-9907180/ . . .
Medscape Infectious Diseases
1.04.2025
A federal judge ordered a Johnson & Johnson unit on Friday to pay the U.S. government $1.64 billion after a jury found it liable in a whistleblower lawsuit for illegally. . Reuters Health Information
Medscape Infectious Diseases
28.03.2025
Nucleoside reverse transcriptase inhibitor resistance does not affect efficacy when adults with HIV suppressed on bPI-based regimen switch to bictegravir plus emtricitabine plus tenofovir alafenamide. . Medscape Medical News
Medscape Infectious Diseases
25.03.2025
There could be 2,000 new HIV infections a day across the world and a ten-fold increase in related deaths if funding frozen by the United States is not restored or replaced,. . Reuters Health Information
Morbidity and Mortality Weekly Report (MMWR)
20.03.2025
This report describes adolescent girls and young women with functional disabilities had who higher prevalence of experiencing sexual, physical and emotional violence.
Medscape Infectious Diseases
20.03.2025
Doubling the dose of tuberculosis treatment did not drive up rates of depression and anxiety. . Medscape Medical News
Medscape Infectious Diseases
19.03.2025
Visuospatial scores improved significantly with semaglutide compared with placebo. . Medscape Medical News
Medscape Infectious Diseases
19.03.2025
The U.S. health department said on Tuesday it is reviewing the Centers for Disease Control and Prevention's HIV prevention division for overlap with other agencies but no. . Reuters Health Information
Medscape Infectious Diseases
18.03.2025
The Trump administration's decision to pause U.S. foreign aid has 'substantially disrupted' supply of HIV treatments in eight countries, which could soon run out of these. . Reuters Health Information
Medscape Infectious Diseases
17.03.2025
Dolutegravir plus lamivudine shows comparable efficacy and safety with standard-of-care three-drug regimen in patients with HIV without preliminary drug resistance testing in a phase 4 trial. . Medscape Medical News
ProMED
15.03.2025
. . . HIV/AIDS - FIJI: INCREASED NUMBERS, DRUG USE, BLUETOOTHING. **********************************************************. A ProMED-mail post. www.promedmail.org. ProMED-mail is a program of the. International Society for Infectious Diseases. www.isid.org . Date: Fri 14 Mar 2025 . Source: Australian Broadcasting Corporation [edited] . www.abc.net.au/news/2025-03-14/hiv-fiji-pacific-drug-use-addiction-bluetoothing/105043402 . . .
Medscape Infectious Diseases
12.03.2025
The health clinic where Alice Okwirry collects her HIV medication in Kenya's capital Nairobi has been rationing supplies of antiretrovirals to one-month refills since the. . Reuters Health Information
Medscape Infectious Diseases
8.03.2025
The Trump administration's dismantling of the U.S. Agency for International Development has targeted a huge range of programs for cuts, from a few thousand dollars for an. . Reuters Health Information
Medscape Infectious Diseases
7.03.2025
Some lifesaving health projects that had their U.S. funding contracts abruptly terminated last week have received letters reversing that decision, several of the groups told. . Reuters Health Information

DSI på

Følg os på linkedin.com/company/dansk-selskab-for-infektionsmedicin

Nyhedsbrev

Skriv din email adresse og modtag nyheder om hjemmesiden.


© 2025 Dansk Selskab for Infektionsmedicin

CVR: 33634307

www.infmed.dk
Version: 2.2.1
PHP version: 8.0.30
Design: Christian Philip Fischer
Side indlæst på 1.093 s

Cookies og privatliv